跳到正文
MarketHOT
English
摘要
SEC · EDGAR 财务披露·· 13 天前AI 评分18

Tiziana Life Sciences 提交 6-K,宣布将在 BIO-Europe 2026 参会并举办电话会

6-K - Tiziana Life Sciences Ltd (0001723069) (Filer)

AI 导读

Tiziana Life Sciences 于 11 月 9 日提交 6-K,宣布将参加 11 月 9 日至 11 日在德国科隆举行的 BIO-Europe 2026。公司还将于 11 月 9 日举行电话会和网络直播,讨论鼻内 foralumab 治疗非活动性继发进展型多发性硬化症的 IIa 期 INFORM-MS 试验积极顶线结果。

正文

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

November 2026

Commission File Number:  001-38723

Tiziana Life Sciences LTD

(Exact Name of Registrant as Specified in Its Charter)

9th Floor

107 Cheapside

London

EC2V 6DN

(Address of registrant’s principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒         Form 40-F ☐

INFORMATION CONTAINED IN THIS REPORT ON FORM 6-K

On November 9, 2026, Tiziana Life Sciences LTD (the “Company”) issued this 6K announcing, that it will present at BIO-Europe 2026, taking place November 9–11, 2026, at Koelnmesse in Cologne, Germany. Tiziana is also hosting a conference call and webcast with Key Opinion Leaders today, Monday, November 9, 2026, at 12:00 p.m. ET / 17:00 GMT, to discuss the positive topline results from the Phase 2a INFORM-MS trial of intranasal foralumab in na-SPMS.

The Announcement is furnished herewith as Exhibit 99.1 to this Report on Form 6-K. The information in the attached Exhibits 99.1 is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, or otherwise subject to the liabilities of that Section. This report on Form 6-K is hereby incorporated by reference into the Company’s Registration Statement on Form F-3 (Reg. No. 333-286064) and Form S-8 (Reg. No. 333-293620).

1

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

  TIZIANA LIFE SCIENCES LTD
       
Date: November 9, 2026 By: /s/ Keeren Shah
    Name:  Keeren Shah
    Title: Chief Financial Officer

2

EXHIBIT INDEX

Exhibit No.   Description
99.1   Tiziana Life Sciences LTD Press Release, dated November 9, 2026

3

来源:SEC EDGAR · 本站存档